Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Opdualag (nivolumab and relatlimab-rmbw)- (RELATIVITY-098) | Stage III-IV melanoma | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Milvexian - (AXIOMATIC-SSP) | Stroke prevention (SSP) | Phase 2 | Data Released | Oral | Cardiology |
| Bristol-Myers Squibb Company | Iberdomide | Lupus Erythematosus (SLE) | Phase 2 | Trial Completed | Oral | Immunology |
| Bristol-Myers Squibb Company | Deucravacitinib - (IM011-127) | Ulcerative colitis (UC) | Phase 2 | Trial Discontinued | oral | Gastroenterology |
| Bristol-Myers Squibb Company | BMS-986504 (PRMT5 inhibitor) - (MountainTAP-29) | 1L Metastatic NSCLC (with Homozygous MTAP deletion) | Phase 2/3 | Trial Planned | oral | Oncology |
| Bristol-Myers Squibb Company | Deucravacitinib - (PAISLEY) | Moderate to severe systemic lupus erythematosus (SLE) | Phase 2 | Trial Completed | Oral | Immunology |
| Bristol-Myers Squibb Company | Milvexian - (AXIOMATIC-SSP) | Stroke prevention (SSP) | Phase 2 | Data Released | Oral | Cardiology |
| Bristol-Myers Squibb Company | Iza-bren (izalontamab brengitecan, EGFR x HER3 ADC) - (IZABRIGHT-Breast01) | 1L Triple Negative Breast Cancer (TNBC) | Phase 2/3 | Ongoing | Intravenous | Oncology |
